Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pear Therapeutics, Inc. - Class A Common Stock (NQ: PEAR )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 18, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pear Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why HyreCar Is Trading Higher By 60%, Here Are 63 Stocks Moving In Tuesday's Mid-Day Session
Gainers HyreCar Inc. (NASDAQ: HYRE) jumped 60% to $1.2680 after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist... 
Via Benzinga
South Carolina Department of Corrections and Pear Therapeutics Team up to Support Inmates in Recovery from Substance Use Disorders
From Pear Therapeutics, Inc.
Via Business Wire
Where Pear Therapeutics Stands With Analysts
  Pear Therapeutics (NASDAQ:PEAR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results. 
Via Benzinga
Pear Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference
From Pear Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
Where Pear Therapeutics Stands With Analysts
Within the last quarter, Pear Therapeutics (NASDAQ:PEAR) has observed the following analyst ratings: 
Via Benzinga
Where Pear Therapeutics Stands With Analysts
Within the last quarter, Pear Therapeutics (NASDAQ:PEAR) has observed the following analyst ratings: 
Via Benzinga
Why Baudax Bio Is Trading Lower By 34%; Here Are 26 Stocks Moving Premarket
Gainers Mobile Global Esports Inc. (NASDAQ: MGAM) shares rose 28.1% to $3.33 in pre-market trading after gaining over 5% on Monday. The company recently reported an exclusive compression technology... 
Via Benzinga
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion. 
Via Benzinga
Upstart Digital Health Company, DarioHealth, Announces Significant Contract with National Health Plan Provider, Giving Millions Access to Mental Health Resources
DarioHealth Corp. (NASDAQ: DRIO) recently announced 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.8% to $0.97 during Monday's after-market session. The company's market cap stands at $31.6 million. 
Via Benzinga
Pear Therapeutics Reports Second Quarter 2022 Results
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®
From Pear Therapeutics, Inc.
Via Business Wire
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. 
Via Benzinga
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session
Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year. 
Via Benzinga
Pear Therapeutics and SelectHealth Announce Coverage to Provide Access to FDA-Authorized Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics and Cove Behavioral Health to Provide Patients Access to Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to be Added to Russell US Index Series
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Issue Second Quarter 2022 Financial Results on Thursday, August 11, 2022
From Pear Therapeutics, Inc.
Via Business Wire
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 137 stocks made new 52-week lows. 
Via Benzinga
Pear Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Pear Therapeutics's (NASDAQ:PEAR) reported sales totaled $2.75 million. Despite a 62.5% increase in earnings, the company posted a loss of $23.86... 
Via Benzinga
Pear Therapeutics to Participate in the Cowen 7th Annual FutureHealth Conference
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Announces Three New Board Members
From Pear Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Pear Therapeutics Announces New 12-Month Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Treated with reSET-O®
From Pear Therapeutics, Inc.
Via Business Wire
93 Biggest Movers From Yesterday
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
70 Stocks Moving In Monday's Mid-Day Session
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.